VIG vs XBI
Vanguard Dividend Appreciation ETF vs SPDR S&P Biotech ETF
- • VIG has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • VIG pays a higher dividend yield (1.51%).
Side-by-side metrics
| Metric | VIG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.51% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $124.65B | $8.30B |
YTD return | 4.98% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.79 | 1.09 |
P/E ratio | 26.45 | — |
Last price | $228.11 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VIG top holdings
| AVGO | Broadcom Inc | 4.07% |
| AAPL | Apple Inc | 4.03% |
| MSFT | Microsoft Corp | 3.81% |
| JPM | JPMorgan Chase & Co | 3.53% |
| LLY | Eli Lilly and Co | 3.48% |
| XOM | Exxon Mobil Corp | 3.38% |
| JNJ | Johnson & Johnson | 2.81% |
| WMT | Walmart Inc | 2.60% |
| V | Visa Inc Class A | 2.26% |
| COST | Costco Wholesale Corp | 2.11% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VIG
VIG (Vanguard Dividend Appreciation ETF) is US companies with a record of growing dividends. Managed by Vanguard, the fund carries $124.6B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.51%. Its largest holding is Broadcom Inc (AVGO), which represents 4.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 5.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.